​​​​​​​PsA Treatment Options Expand - Report - MDSpire

​​​​​​​PsA Treatment Options Expand

Phase 3 POETYK trial results support FDA approval of deucravacitinib for adults with active PsA.

  • By

  • Kathryn Wighton

  • March 9, 2026

  • 3 min

Share

Clinical Report: PsA Treatment Options Expand

Overview

Deucravacitinib (Sotyktu) has been approved by the FDA for adults with active psoriatic arthritis, marking it as the first TYK2 inhibitor for this condition. The drug demonstrated significant improvements in disease activity outcomes compared to placebo in two phase 3 trials.

Background

Psoriatic arthritis (PsA) is a chronic inflammatory disease that can lead to joint damage and disability. The introduction of new treatment options, such as deucravacitinib, is crucial for improving patient outcomes and expanding therapeutic strategies. This approval reflects ongoing advancements in targeted therapies for inflammatory conditions.

Data Highlights

TrialACR20 Response (Deucravacitinib)ACR20 Response (Placebo)ACR50 Response (Deucravacitinib)ACR50 Response (Placebo)ACR70 Response (Deucravacitinib)ACR70 Response (Placebo)
POETYK PsA-154%34%24%14%12%5%
POETYK PsA-254%39%29%16%10%5%

Key Findings

  • Deucravacitinib is the first TYK2 inhibitor approved for active psoriatic arthritis.
  • In phase 3 trials, ACR20 response rates were 54% for deucravacitinib compared to 34-39% for placebo.
  • ACR50 and ACR70 responses were also significantly higher in patients treated with deucravacitinib.
  • The safety profile was consistent with previous studies, with common adverse reactions including upper respiratory infections and herpes simplex.
  • Both trials included patients with varying prior treatment histories, enhancing the generalizability of the findings.

Clinical Implications

The approval of deucravacitinib provides clinicians with a new oral treatment option for patients with active psoriatic arthritis, particularly those who have not responded to traditional therapies. Monitoring for potential adverse effects, especially infections, will be essential in managing patient safety.

Conclusion

The introduction of deucravacitinib represents a significant advancement in the treatment landscape for psoriatic arthritis, offering improved efficacy and a new mechanism of action for managing this complex disease.

References

  1. Bristol Myers Squibb, Press Release, 2026 -- PsA Treatment Options Expand
  2. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update | Annals of the Rheumatic Diseases
  3. The ASCO Post — Investigational PSMA-Targeted Radioligand Reduced Off-Target Uptake in Prostate Cancer Models
  4. The ASCO Post — Advanced Imaging May Uncover Hidden Metastases in High-Risk Prostate Cancer Cases
  5. the asco post — Investigational PSMA-Targeted Radioligand Reduced Off-Target Uptake in Prostate Cancer Models
  6. The ASCO Post — Adding LuPSMA to Standard Care Improves Outcomes in Castration-Resistant Prostate Cancer
  7. FDA Approves Bimekizumab for Three Rheumatologic Conditions
  8. Approval Label_214958s002lbl.pdf
  9. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update | Annals of the Rheumatic Diseases

Original Source(s)

​​​​​​​PsA Treatment Options Expand

  • by Kathryn Wighton

  • March 9, 2026

Related Content

RA Prescribing Patterns Shift Over 15 Years

An aging Japanese cohort with rheumatoid arthritis saw increasing use of targeted synthetic therapies as glucocorticoid use declined.

Organ Damage, BMI Linked to Fatigue in SLE

Cross-sectional study suggests fatigue is associated with damage accrual and body mass, not disease activity

Side Effects: Salt, Steroids, and Second Brains

So get this: sodium may track with memory decline (in men), steroids might not be “immunosuppressive” in the ICU, and second pregnancies reshape the brain differently than first. Same theme: biology is less binary than we teach it.